Den Europæiske Union - dansk - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - radionuklidbilleddannelse - diagnostiske radioaktive lægemidler - dette lægemiddel er kun til diagnostisk brug. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

smithkline beecham plc - rosiglitazone, metformin-hydrochlorid - diabetes mellitus, type 2 - narkotika anvendt i diabetes - avandamet er indiceret til behandling af type 2-diabetes mellitus patienter, især overvægtige patienter:der ikke er i stand til at opnå tilstrækkelig glykæmisk kontrol ved deres maksimalt tolereret dosis af oral metformin alene. i triple oral behandling med sulphonylurea hos patienter med utilstrækkelig glykæmisk kontrol på trods af dobbelt oral behandling med deres maksimalt tolereret dosis af metformin og et sulphonylurea (se afsnit 4.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

merz pharmaceuticals gmbh   - memantinhydrochlorid - alzheimers sygdom - andre anti-demensmidler - behandling af patienter med moderat til svær alzheimers sygdom.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

accord healthcare b.v. - metforminhydrochlorid - filmovertrukne tabletter - 500 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

teva b.v. - metforminhydrochlorid, vildagliptin - filmovertrukne tabletter - 50+850 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

krka d.d. novo mesto - metforminhydrochlorid, vildagliptin - filmovertrukne tabletter - 50+850 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

sandoz a/s - metforminhydrochlorid, vildagliptin - filmovertrukne tabletter - 50+850 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

xellia pharmaceuticals aps - colistimethatnatrium - pulver til injektions-/infusionsvæske, opløsning - 1.000.000 ie

Den Europæiske Union - dansk - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, type 2 - narkotika anvendt i diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 og 5. 1 for tilgængelige data på forskellige kombinationer).

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

krka d.d. novo mesto - metforminhydrochlorid, sitagliptin - filmovertrukne tabletter - 50+850 mg